Weekly Investment Analysts’ Ratings Updates for BioMarin Pharmaceutical (BMRN)

A number of firms have modified their ratings and price targets on shares of BioMarin Pharmaceutical (NASDAQ: BMRN) recently:

• 9/16/2026 – BioMarin Pharmaceutical had its “outperform” rating reaffirmed by BMO Capital Markets.
• 9/10/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.
• 9/3/2026 – BioMarin Pharmaceutical was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 9/1/2026 – BioMarin Pharmaceutical had its price target raised by Piper Sandler from $88.00 to $90.00. They now have an “overweight” rating on the stock.
• 8/31/2026 – BioMarin Pharmaceutical had its price target raised by Jefferies Financial Group Inc. from $104.00 to $105.00. They now have a “buy” rating on the stock.
• 8/31/2026 – BioMarin Pharmaceutical had its price target raised by HC Wainwright from $59.00 to $60.00. They now have a “neutral” rating on the stock.
• 8/26/2026 – BioMarin Pharmaceutical was given a new $88.00 price target by UBS Group AG.
• 8/19/2026 – BioMarin Pharmaceutical is now covered by BMO Capital Markets. They set an “outperform” rating and a $98.00 price target on the stock.
• 8/18/2026 – BioMarin Pharmaceutical was upgraded by BMO Capital Markets to “strong-buy”.
• 8/18/2026 – BioMarin Pharmaceutical had its price target lowered by HC Wainwright from $60.00 to $59.00. They now have a “neutral” rating on the stock.
• 8/17/2026 – BioMarin Pharmaceutical had its price target raised by Piper Sandler from $82.00 to $88.00. They now have an “overweight” rating on the stock.
• 8/17/2026 – BioMarin Pharmaceutical had its price target raised by Barclays PLC from $105.00 to $111.00. They now have an “overweight” rating on the stock.
• 8/11/2026 – BioMarin Pharmaceutical was downgraded by Weiss Ratings from “hold (c-)” to “sell (d)”.
• 8/10/2026 – BioMarin Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $111.00 to $114.00. They now have a “buy” rating on the stock.
• 8/8/2026 – BioMarin Pharmaceutical was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/7/2026 – BioMarin Pharmaceutical had its price target raised by Oppenheimer Holdings, Inc. from $95.00 to $97.00. They now have an “outperform” rating on the stock.
• 8/7/2026 – BioMarin Pharmaceutical had its price target raised by Morgan Stanley from $119.00 to $124.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – BioMarin Pharmaceutical had its price target raised by HC Wainwright from $50.00 to $60.00. They now have a “neutral” rating on the stock.

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for rare and serious diseases. Founded in 1997 and headquartered in San Rafael, California, the company specializes in treatments for conditions that often have limited or no available therapeutic options, including inherited metabolic disorders, skeletal diseases, and certain bleeding disorders.

BioMarin’s marketed products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for late-infantile neuronal ceroid lipofuscinosis type 2, Palynziq and Kuvan for phenylketonuria, and Voxzogo for achondroplasia in children with open growth plates.